Samsung Highlights New Biosimilar Switching Data At EULAR
This article was originally published in PharmAsia News
South Korea's Samsung Bioepis, which is tapping the US market with its infliximab biosimilar, has presented new clinical switching data for its etanercept product Benepali, its infliximab biosimilar Flixabi, and SB5, an investigational version of adalimumab, at the annual European Congress on Rheumatology.
You may also be interested in...
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Korean venture Helixmith faces another setback following a missed Phase III endpoint for its plasmid DNA neuropathy candidate, with its shares plunging after it warned of a possible delay in a planned rights offering, amid concerns from minority shareholders over other investment losses.